关于辉瑞和科兴的副作用，这里真有一个“真实世界的香港数据”

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00088-3/fulltext#articleInformation

Safety profiles of BNT162b2 and CoronaVac in Hong Kong vaccinees

After the first vaccination, the overall incidence rate of any adverse reactions was higher for BNT162b2 than CoronaVac (79.4% [27/34] versus 53.6% [15/28], P=0.03). The most common adverse reaction was the injection-site pain (73.5% [25/34] versus 35.7% [10/28], P=0.003), followed by fatigue (41.2% [14/34] versus 25.0% [7/28], P=0.18) and myalgia (17.6% [6/34] versus 14.3% [4/28], P=0.991), respectively (Fig. S2a). After the second vaccination, the overall incidence of any adverse reactions was consistently higher for BNT162b2 than CoronaVac (88.2% [30/34] versus 57.1% [16/28], P=0.005), including the major injection-site pain (64.7% [22/34] versus 53.6% [15/28], P=0.374) and other systematic symptoms (e.g., headache, fever and fatigue) (Fig. S2b). Moreover, significantly more BNT162b2-vaccinees had more than two adverse reactions (86.7% [26/30] versus 31.3% [5/16], P < 0.001). Most of the adverse reactions, however, were considered tolerable with an average recovery time of 48-72 hours. No vaccine-associated severe adverse reactions were reported among our study subjects.